AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3545744
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg Nisoldipine
Trial: 24444117
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate administered in the prehospital setting
Trial: 19708473
Drug: Sensory Integrative
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sensory Integrative (SI) therapy
Trial: 12229307
Drug: Omeprazole 80
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole 80 mg daily for three days
Trial: 12592331
Drug: High-dose methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methylprednisolone (HDMP)
Trial: 7915989
Drug: Low-dose methylprednisolone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose methylprednisolone (LDMP)
Trial: 2643500
Drug: Heparin sodium
RxNorm normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin sodium 10 units/mL
Trial: 31277885
Drug: Warfarin (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (group 2)
Trial: 17445933
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart with metformin 500 mg t.i.d. for 90 days
Trial: 17445933
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human insulin with metformin 500 mg t.i.d. for 90 days
Trial: 15600248
Drug: Maribavir (DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maribavir (DNA synthesis inhibitor)
Trial: 15899652
Drug: alpha-tocopherol (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-tocopherol (800 mg/day)
Trial: 8621850
Drug: Zileuton (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zileuton (600 mg orally four times a day for 8 days)
Trial: 1742650
Drug: Threshold allergen
RxNorm normalized name: catfish allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Threshold allergen dose
Trial: 1742650
Drug: Higher allergen
RxNorm normalized name: catfish allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher allergen dose (x 10 threshold)
Trial: 7139396
Drug: d‐tubocurarine 0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐tubocurarine 0.04 mg.kg‐1 and atropine 0.01 mg.kg‐1
Trial: 7139396
Drug: d‐tubocurarine 0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐tubocurarine 0.04 mg.kg‐1 only
Trial: 29524000
Drug: OLE in
RxNorm normalized name: fomepizole Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OLE in solution (25 g sucrose)
Trial: 29524000
Drug: OLE in
RxNorm normalized name: fomepizole Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OLE in capsules or solution (50 g sucrose or glucose)
Trial: 24531433
Drug: Contrast water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast water therapy (alternating 1 minute 38° C and 1 minute 15° C water immersion)
Trial: 24531433
Drug: Contrast water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast water therapy and contrast showers
Trial: 20403600
Drug: Sedative music
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedative music for 30 minutes
Trial: 12047490
Drug: nabumetone 1000
RxNorm normalized name: nabumetone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nabumetone 1000 mg twice daily
Trial: 12047490
Drug: meloxicam 7.5
RxNorm normalized name: meloxicam 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meloxicam 7.5 mg twice daily
Trial: 12047490
Drug: indomethacin 50
RxNorm normalized name: indomethacin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: indomethacin 50 mg
Trial: 7673658
Drug: Cyproheptadine augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproheptadine augmentation of haloperidol
Trial: 30691750
Drug: No thermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No thermal agent (control)
Trial: 29441909
Drug: Esmolol (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (0.3 mg/kg before intubation, continuous perfusion at 50 μg/kg/min during operation)
Trial: 24081158
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human GH (rhGH) (33-50 μg kg(‐1) day(‐1))
Trial: 23747582
Drug: Group Cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Cognitive Behavioral Therapy (CBT)
Trial: 20084879
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of PCV7
Trial: 16948824
Drug: Broad-band UVB
RxNorm normalized name: Band-Aid Hurt-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broad-band UVB phototherapy plus oral acyclovir (800 mg five times a day for 10 days); UVB starting at 20 mJ/cm², increasing by 10 mJ/cm² per session, max 100 mJ/cm², 3 times a week for up to 15 sessions.
Trial: 16948824
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir (800 mg five times a day for 10 days) only (control group).
Trial: 11421836
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of droperidol 15 microg kg(‐1) and ondansetron 100 microg kg(‐1)
Trial: 3566859
Drug: Digoxin-Pharbita 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin-Pharbita 0.25 mg (Product A)
Trial: 3566859
Drug: Reference drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference drug B (Product B)
Trial: 31799993
Drug: Maintenance of
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance of Antidepressant Medication (ADM)
Trial: 31799993
Drug: Antidepressant Medication
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant Medication (ADM) alone
Trial: 25248345
Drug: Subunit Agrippal
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subunit Agrippal vaccine
Trial: 21883001
Drug: Haematococcus astaxanthin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haematococcus astaxanthin (ASX) 5 mg
Trial: 21883001
Drug: Haematococcus astaxanthin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haematococcus astaxanthin (ASX) 20 mg
Trial: 21883001
Drug: Haematococcus astaxanthin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haematococcus astaxanthin (ASX) 40 mg
Trial: 10630442
Drug: L. acidophilus
RxNorm normalized name: L. acidophilus/L.bulgaricus ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. acidophilus LB
Trial: 9360340
Drug: Oresol-G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oresol-G
Trial: 3899198
Drug: Dextroamphetamine (Dex)
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine (Dex) 15 mg
Trial: 3899198
Drug: Fenfluramine (Fen)
RxNorm normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenfluramine (Fen) 40 mg
Trial: 29887334
Drug: Bevacizumab 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 0.25 mg
Trial: 29887334
Drug: Bevacizumab 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 0.125 mg
Trial: 29887334
Drug: Bevacizumab 0.063
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 0.063 mg
Trial: 29887334
Drug: Bevacizumab 0.031
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 0.031 mg
Trial: 29887334
Drug: Bevacizumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (all doses)
Trial: 25704503
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose MFGM tablets (6.5 g) for 4 weeks
Trial: 23335901
Drug: Disulfiram (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disulfiram (250 mg/day, N=32)
Trial: 18655523
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment at 0.067 mg/kg/day
Trial: 18655523
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment at 0.033 mg/kg/day
Trial: 16968587
Drug: Cefdinir (14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefdinir (14 mg/kg divided BID)
Trial: 16968587
Drug: High-dose amoxicillin/clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose amoxicillin/clavulanate (90/6.4 mg/kg divided BID)
Trial: 16968587
Drug: High-dose amoxicillin/clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose amoxicillin/clavulanate
Trial: 15523393
Drug: Radiochemotherapy (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiochemotherapy (200 mg/m²/day of intravenous 5-fluorouracil and 5040 cGy of radiotherapy)
Trial: 11515713
Drug: Willow bark
RxNorm normalized name: Willow bark
DrugBank: Willow bark (DB14691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Willow bark extract (Assalix) 240 mg salicin per day (group W240)
Trial: 11515713
Drug: Willow bark
RxNorm normalized name: Willow bark
DrugBank: Willow bark (DB14691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Willow bark extract (Assalix) 120 mg salicin per day (group W120)
Trial: 11515713
Drug: Conventional treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatments only (group C)
Trial: 9791144
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg) plus Icatibant (100 microg/kg)
Trial: 9791144
Drug: Losartan (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (75 mg)
Trial: 7842496
Drug: Single case
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single case studies with randomized treatment
Trial: 27099247
Drug: Corticotropin-releasing factor
RxNorm normalized name: corticotropin-releasing factor
DrugBank: Corticorelin ovine triflutate (DB09067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticotropin-releasing factor (CRF) injection
Trial: 24560674
Drug: Monovalent replication-deficient
RxNorm normalized name: covid-19, viral vector, non-replicating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent replication-deficient delNS1-H1N1 influenza virus vaccine (7.7log10TCID50/volunteer)
Trial: 24560674
Drug: Monovalent replication-deficient
RxNorm normalized name: covid-19, viral vector, non-replicating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent replication-deficient delNS1-H1N1 influenza virus vaccine
Trial: 20444742
Drug: Aciclovir 800
RxNorm normalized name: Aciclovir 800 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aciclovir 800 mg twice daily for 5 days
Trial: 10950228
Drug: Tri-iodothyronine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tri-iodothyronine treatment (2 microg/kg bodyweight on day 1, 1 microg/kg bodyweight on subsequent days up to 12 days)
Trial: 10950228
Drug: Tri-iodothyronine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tri-iodothyronine treatment
Trial: 1282179
Drug: Nicorandil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (10 mg b.i.d. increased to 20 mg b.i.d. after 4 weeks)
Trial: 1282179
Drug: Nicorandil (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (20 mg b.i.d.)
Trial: 1282179
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Nicorandil and Nifedipine)
Trial: 6429850
Drug: AIO solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIO solution (40 g crystalline L-aminoacids, 38 g fat, 75 g sorbitol, 45 g xylitol in 1000 ml)
Trial: 6429850
Drug: AIO solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIO solution
Trial: 20536366
Drug: Conventional amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional amphotericin B at 0.7 mg/kg/day
Trial: 20536366
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B at 3 mg/kg/day
Trial: 20536366
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B at 6 mg/kg/day
Trial: 14964349
Drug: nonretarded test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nonretarded test medication
Trial: 14964349
Drug: retarded reference
RxNorm normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: retarded reference formulation
Trial: 10642807
Drug: Mobilizing therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobilizing therapy and first transplant
Trial: 10642807
Drug: Transplant-related chemotherapy
RxNorm normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transplant-related chemotherapy
Trial: 2062997
Drug: 7 days
RxNorm normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days supply of medication
Trial: 2062997
Drug: 14 days
RxNorm normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 14 days supply of medication
Trial: 2062997
Drug: New discharge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New discharge letter with prescription details
Trial: 25407966
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment group (radiotherapy + LMP1-targeted DNAzyme)
Trial: 23135655
Drug: Cetaphil Dermacontrol
RxNorm normalized name: CETAPHIL
DrugBank: Octocrylene (DB09535)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetaphil Dermacontrol Moisturizer (CDM) + tretinoin cream 0.05%
Trial: 23135655
Drug: tretinoin cream
RxNorm normalized name: Tretinoin Cream
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tretinoin cream 0.05%
Trial: 15883262
Drug: Atorvastatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (80 mg; two 40‐mg tablets once daily)
Trial: 9607039
Drug: Oral inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral inactivated enterotoxigenic Escherichia coli vaccine (lot 001)
Trial: 9607039
Drug: Oral inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral inactivated enterotoxigenic Escherichia coli vaccine (lot 003)
Trial: 9607039
Drug: Oral inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral inactivated enterotoxigenic Escherichia coli vaccine
Trial: 2667153
Drug: Ofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (200 mg twice a day for seven days)
Trial: 2667153
Drug: Erythromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (500 mg twice a day for seven days)
Trial: 790287
Drug: Oral theophylline
RxNorm normalized name: theophylline Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral theophylline (10 mg/kg three times per day)
Trial: 21715702
Drug: Pramipexole (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole (0.25 mg)
Trial: 21993434
Drug: Hoodia gordonii
RxNorm normalized name: Hoodia gordonii
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hoodia gordonii purified extract (HgPE) 1110 mg, 2 servings/day for 15 days
Trial: 1382540
Drug: Cryotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryotherapy and inosine pranobex 60 mg/kg/day for 1 week each month
Trial: 26752328
Drug: Individual in
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual in vivo exposure therapy (iVET)
Trial: 26752328
Drug: Individual virtual
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual virtual reality exposure therapy (VRET)
Trial: 22343689
Drug: 5 ml
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml fibrin sealant
Trial: 22343689
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml fibrin sealant
Trial: 12374512
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with antihypertensive therapy (nitrendipine 10-40 mg/d, possibly with enalapril maleate 5-20 mg/d and/or hydrochlorothiazide 12.5-25 mg/d)
Trial: 12374512
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with antihypertensive therapy
Trial: 30499618
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 plus Calcium (1200 mg daily)
Trial: 28333510
Drug: ADHD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADHD treatment (medication + parent training)
Trial: 28333510
Drug: Reading treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reading treatment (reading instruction)
Trial: 28333510
Drug: Combined ADHD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined ADHD + reading treatment
Trial: 25092686
Drug: β-adrenergic antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: β-adrenergic antagonist propranolol
Trial: 21779819
Drug: Bazedoxifene 40/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bazedoxifene 40/20 mg
Trial: 21779819
Drug: Bazedoxifene 20
RxNorm normalized name: bazedoxifene 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bazedoxifene 20 mg (higher-risk subgroup)
Trial: 21779819
Drug: Bazedoxifene 20
RxNorm normalized name: bazedoxifene 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bazedoxifene 20 and 40/20 mg (combined data)
Trial: 19171224
Drug: Platelet-inhibitory doses
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-inhibitory doses of aspirin (maximal total dose: 400mg/day)
Trial: 15826746
Drug: Neridronate (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neridronate (25 mg intramuscular monthly)
Trial: 15826746
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and cholecalciferol (500 mg of elemental calcium and 400 IU cholecalciferol daily)
Trial: 15826746
Drug: Neridronate (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neridronate (25 mg intramuscular monthly) with calcium and cholecalciferol
Trial: 8199810
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate 60 mg/kg infused intravenously
Trial: 31900166
Drug: Caffeine supplementation
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine supplementation (6 mg/kg)
Trial: 20620788
Drug: Hamstring donor-site
RxNorm normalized name: Donor Human Stool
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hamstring donor-site block (20-mL injection of 0.25% bupivacaine)
Trial: 20620788
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (no hamstring donor-site block)
Trial: 16115337
Drug: VPP and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VPP and IPP 1.8 mg
Trial: 16115337
Drug: VPP and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VPP and IPP 2.5 mg
Trial: 16115337
Drug: VPP and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VPP and IPP 3.6 mg
Trial: 15544888
Drug: Metronidazole 1600
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole 1600 mg
Trial: 11060718
Drug: Oestrogen replacement,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestrogen replacement, anti-inflammatory agents, free radical scavengers, anti-oxidants, MAO-B inhibitors